Treatment options for metastatic hormone-sensitive prostate cancer

Lancet Oncol. 2022 Oct;23(10):1234-1235. doi: 10.1016/S1470-2045(22)00520-4. Epub 2022 Sep 5.

Authors

Louise Kostos¹, Declan G Murphy²

Affiliations

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
² Department of Urology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: declan.murphy@petermac.org.

PMID: 36075259
DOI: 10.1016/S1470-2045(22)00520-4

No abstract available

Publication types

Comment

MeSH terms

Androgen Antagonists / adverse effects
Hormones
Humans
Male
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / pathology

Substances

Androgen Antagonists
Hormones